MENLO PARK, Calif., Feb. 2, 2012 /PRNewswire/ -- BioParadox, Inc., a regenerative medicine company pioneering point-of-care biologic treatments for cardiovascular disease, today announced a strategic alliance with Fogarty Institute for Innovation.
"We are delighted to begin working with the Fogarty Institute for Innovation known for its commitment to developing creative solutions for patients with challenging problems. The Fogarty Institute's unique programs to support medical innovators by providing important business, technical, and clinical input offers BioParadox the opportunity to rapidly advance its novel Platelet-Cell Therapy (PCT) for the treatment of cardiovascular disease," said Allan Mishra, MD, Founder of BioParadox.
Speaking at the January 2012 Conference on Cell Therapy for Cardiovascular Disease in New York, Todd Brinton, MD, presented data supporting PCT for peripheral vascular disease. BioParadox was also recently awarded a United States patent covering this technology.
BioParadox is innovating the use of Platelet-Cell Therapy (PCT) for the treatment of cardiovascular disease. The company's first products, VitaKine® and RevaTen®, are proprietary formulations that have been shown to enhance cardiovascular function. They are produced exclusively by BioParadox.
About the Fogarty Institute for Innovation
The Fogarty Institute for Innovation is an educational 501(c) (3) non-profit committed to the mission of improving patient care by supporting revolutionary medical innovation. The Institute offers promising innovators world-class technical and business mentoring, laboratory space, and clinical support to propel medical innovations from conception to application. Further information is available at www.fogartyinstitute.org.
|SOURCE BioParadox, Inc.|
Copyright©2010 PR Newswire.
All rights reserved